Authors: Frederik Nietvelt, Imré Van Herreweghe, Vincent Godschalx, Filiep Soetens
Categories: Perioperative Medicine
Source: European Journal of Anaesthesiology
Extravascular injection of neuromuscular blocking drugs (NMBDs) can cause a neuromuscular block because of systemic absorption. Currently, there are no guidelines available on managing extravasation of NMBDs. This article reviews the available literature on extravasation of NMBDs. Medline and Embase databases were searched for studies concerning the paravenous or subcutaneous injection of NMBDs. Nine articles were included consisting of seven case reports, one case series and one clinical trial. Rocuronium was used as primary NMBD in nine cases, vecuronium in two cases and pancuronium in one case. Although there exists significant heterogeneity between the reported information in the included studies, the majority of the case reports describe a slower onset, with a median delay of 20 min and prolonged duration of the neuromuscular block. Nine patients had a residual neuromuscular block at the end of the surgery. Postoperative monitoring in the recovery room was prolonged (median time 4 h). Most studies suggest that the delay in NMBD onset and recovery is caused by the formation of a subcutaneous depot, from which the NMBD is slowly absorbed into the systemic circulation. According to the current literature, extravasation of NMBDs results in an unpredictable neuromuscular block. Strategies to prevent potentially harmful side effects, such as frequent train-of-four (TOF) monitoring, the use of NMBD reversal agents and prolonged length of stay in the postanaesthesia care unit (PACU), should be considered. This article suggests a clinical pathway that can be used after extravascular injection of NMBDs.
Neuromuscular blocking drugs (NMBDs) are usually administered by an intravenous injection, but accidental extravasation may occur when a peripheral intravenous catheter is not positioned correctly. Risk factors for extravasation are small or fragile veins, advanced age, obesity, multiple venipunctures, high injection pressure, poor cannula fixation, the presence of disseminated skin diseases and patient movement during cannula placement.^1^ One study found that up to 39% of the cannulas were dislocated after 72 h.^2^ Depending on the injected drug, leakage in the surrounding extravascular tissue may cause harmful effects such as local irritation or even tissue necrosis.^3^ Moreover, the injected drug may be absorbed into the circulation and cause systemic effects.
As NMBDs are often used during induction of anaesthesia, it is likely that anaesthetists may encounter accidental extravasation of NMBDs. However, little is known about the absorption of NMBDs injected into the subcutaneous tissue and their effect on the onset and the duration of the neuromuscular block. This review aims to summarise the current evidence on extravasation of NMBDs and its systemic adverse effects. Additionally, a flowchart will be presented to guide clinical decision-making after the extravasation of NMBDs.
The recommendations and checklist from the PRISMA 2020 statement (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) were used to construct this narrative review. A literature search was performed on 5 February 2023 in the Ovid MEDLINE and Ovid EMBASE database using the search terms ‘rocuronium’, ‘pancuronium’, ‘vecuronium’, ‘atracurium’, ‘cisatracurium’, ‘mivacurium’ or ‘succinylcholine’ in combination with ‘subcutaneous’, ‘paravenous’, ‘extravasation’ or ‘extravascular leakage’.
All abstracts and titles that contained a combination of these search terms, were published before February 2023 and were written in English, were considered. Three authors assessed the articles independently for their relevance. The exclusion criteria were defined as the NMBDs were injected intramuscularly, only the abstract was available, articles concerning the paediatric population or animals and studies where agents other than NMBD agents were injected subcutaneously. References of the selected articles were also screened using the above-mentioned exclusion criteria.
The following variables were extracted from the selected age, sex, weight, type of NMBD, injection site, difficult intravenous insertion, intravenous cannula already in situ, dose of NMBD (subcutaneous, intravenous and total dose), onset and duration of neuromuscular block, reversal of the neuromuscular block [time, train-of-four (TOF) count or ratio, agent and dose], type of surgery and duration of postoperative monitoring after extubation. The articles were also screened for risk factors that could influence the absorption and metabolism of NMBDs such as peripheral vascular disease, skin oedema, chronic renal failure, hepatic insufficiency, obesity, use of anticonvulsants, prolonged immobility and burns.
The initial search revealed 77 articles after removal of duplicates. From these 77 articles, 71 were excluded based on the exclusion criteria. Most articles were excluded because no extravasation of NMBDs occurred. Ultimately, our search yielded nine seven case reports,^4–10^ one case series describing four cases^11^ and one article reporting one case report with a consecutive clinical trial.^12^ The flow of the articles can be found in Fig. 1.
Fig. 1 Flow of the articles retrieved on Embase and Medline.
The demographics of the patient and characteristics of the intravenous insertion and procedure are listed in Table 1. The median age was 59 years, the male/female distribution was 6/6 with an average BMI of 25 kg m^−2^. Two cases reported the presence of the intravenous cannula upon arrival in the operating room.^6,8^ Three cases reported difficult insertion of the intravenous cannula.^7,8,10^
Table 2 shows the characteristics of the subcutaneous injection of NMBDs. Rocuronium was used in nine cases,^4–8,11^ vecuronium in two cases^9,10^ and pancuronium in one case.^12^ No case reports were retrieved describing the extravasation of atracurium, cisatracurium, mivacurium or succinylcholine. Only three cases mentioned that the intravenous line was checked prior to induction.^6,8,9^ Except for one case, all cases suspected extravasation because of the observation of local swelling.^11^ None of the cases reported a high injection pressure during initial injection. The subcutaneous injections occurred at the level of the upper (n = 8),^4–7,9,11^ the lower (n = 2) extremity^8,12^ and the neck (n = 1).^10^ One case did not specify the site of injection.^11^ The median doses of the subcutaneous injection of rocuronium and vecuronium were 1.1 and 0.1 mg kg^−1^, respectively. The dose of pancuronium was 0.1 mg kg^−1^. After the suspicion of extravasation, seven patients received an additional dose of intravenous NMBD (five patients rocuronium and two patients vecuronium) to facilitate intubation and achieve adequate surgical relaxation before the start of the surgery.^5,7–9,11^ All intravenous top-up doses of NMBDs were administered through a newly placed intravenous line. In four cases, the additional intravenous top-up dose of NMBD was given prior to measurement of the TOF count.^5,9,11^
Apart from the doses mentioned in Table 2, no additional doses of NMBDs were given during the procedure. This resulted in an average total (intravenous with subcutaneous) injected dose of 1.4, 0.2 and 0.1 mg kg^−1^ for rocuronium, vecuronium and pancuronium, respectively. One of these patients received an intravenous injection of vecuronium after an initial extravasation of rocuronium and was thus not included in our calculation of median and average doses.^5^ All cases noticed a delay in onset of neuromuscular blockade, based on TOF measurement and clinical findings such as persistent spontaneous respiration. Three of the cases reported a time of onset of the neuromuscular block with a median delay of 20 min.^4,6,12^ The depth of neuromuscular block throughout the procedure was measured using TOF count or ratio, except for one case in which the patient had extensive burn injuries and placement of electrodes was impossible.^10^ With exception of cases 2 and 9, which did not specify electrode placement, all cases using TOF measurement applied electrodes to the ulnar nerve to evaluate thumb adduction.^4,6–12^ All of the subcutaneous injections of NMBDs were the result of an accidental extravasation during administration of NMBDs through a peripheral venous catheter.
Nine patients had a measured residual neuromuscular block at the end of the surgery.^5,10,11^ The median time of the surgical procedures was 138 min. In nine patients, the neuromuscular block was reversed at the end of the in six patients, sugammadex was administered and in three patients, neostigmine was used.^4–8,10–12^ Sugammadex was only used in cases where rocuronium was administered as sugammadex was not yet available when the case with extravasation of pancuronium occurred. The median time of the administration of the reversal agent after induction was 125 min. The median doses of sugammadex and neostigmine were 3.2 mg kg^−1^ and 45 μg kg^−1^, respectively. The other three patients were sedated and mechanically ventilated in the intensive care unit (ICU) until complete spontaneous recovery of the neuromuscular block occurred.^9,11^ The patients not admitted to the ICU spent a median of 4 h in the recovery room after extravasation of NMBDs.
In most cases, extravasation of NMBDs resulted in an unpredictable neuromuscular block with a delayed onset and prolonged duration of the neuromuscular motor block, requiring reversal agents for safe extubation of the patients.
The plasma concentration of inadvertent extravascular injection of NMBD is dependent on the balance between the rate of absorption of the NMBD from the subcutaneous tissue and the elimination of the NMBD from the plasma. In contrast to intravenous injection where the plasma concentration immediately peaks after administration, subcutaneous injection results in the formation of a subcutaneous depot, from which the NMBD is slowly absorbed into the systemic circulation. The pharmacokinetics of the subcutaneous injected NMBDs may be altered as this depends on many factors such as lipid solubility, protein binding and local tissue perfusion. Therefore, most of the cases report a delayed onset, failure of muscle relaxation and a prolonged duration of action of the NMBDs. However, seven patients received a supplemental dose of NMBDs through a newly placed intravenous cannula and this explains the high total dose of NMBDs administered. The additional dosing of NMBDs makes interpretation of the pharmacokinetic effects after subcutaneous administration of NMBDs impossible. Moreover, the initial dose of NMBD may be partially injected intravenously considering some cases reported a loss of consciousness despite extravasation. Only a small portion of the case reports mention that they had checked the intravenous line prior to intravenous injection. It is hard to know whether this was simply not reported in some articles, but we would like to highlight that not checking the patency of the intravenous line prior to intravenous injection is unsafe practice and that the intravenous line must always be checked, particularly when NMBDs are used or if there is a pre-existing intravenous line of uncertain quality.
Absorption is dependent on the site of the subcutaneous depot. Iwasaki et al.^12^ compared the TOF ratio of the same dose of pancuronium after intravenous injection, subcutaneous injection in the hand and subcutaneous injection in the ankle. The onset of the neuromuscular block in the subcutaneous ankle group was delayed in comparison to the subcutaneous hand group and the intravenous group. Furthermore, twitch recovery was much slower in the subcutaneous ankle group in comparison to the subcutaneous hand group and the intravenous group. In the subcutaneous hand group and the intravenous group, a complete neuromuscular block was observed in all subjects. In contrast, only one patient in the subcutaneous ankle group achieved a complete neuromuscular block. These findings suggest that the site of extravasation influences the pharmacokinetic profile. The skin blood flow is generally higher in the upper than in the lower body half, as a result the absorption from a subcutaneous depot is faster in the upper body half.^13^ This skin blood flow is also increased by general anaesthesia.^14^ NMBDs injected in more vascularised regions will likely have a faster onset and recovery than regions that are less vascularised. For the same reason, factors that affect the local circulation such as diabetes and atherosclerosis, may decrease the absorption of the subcutaneous NMBD, making it very difficult to predict its onset and duration of action. Longer duration of action may occur in patients when elimination is impaired, such as in chronic renal failure, where rocuronium has a 37% longer elimination half-time.^15^
This article reviewed the literature on extravasation of NMBDs, but there are several limitations.
First, few randomised controlled trials are available, and most literature consists of case reports. As a result, there is a lot of heterogeneity between the different reports. Furthermore, because of the small sample size, no statistical analysis was performed.
Second, we were not able to retrieve articles that discussed the subcutaneous injection of atracurium, cisatracurium, mivacurium or succinylcholine. Extravasation of short-acting NMBDs, such as succinylcholine or mivacurium, might not be of clinical importance because of a faster elimination than absorption rate.
Third, we could not extract any data from these case reports concerning the delayed extubation time, incidence of postreversal recurarisation nor the quality of reversal.
Last, the topic of extravasation of NMBDs remains subject to publication bias. Cases with a bad or good outcome may be underreported in the literature. Clinicians may not have related the bad outcome to extravasation of NMBDs. Therefore, it would be beneficial to have qualitative randomised clinical trials that examined the effects of subcutaneous injection of NMBDs.
A clinical pathway based on current literature is suggested in Fig. 2. Preventive measures include correct labelling of medication as well as assessing the quality of the intravenous line. If an intravenous cannula is present, the injection site should be checked for oedema, inflammation and pain. We recommend that the administration of NMBDs via an intravenous cannula with absence of backflow or increased injection pressure should be handled with caution.
Fig. 2 Management pathway
After suspicion of extravasation, a new intravenous line should be secured as soon as possible to ensure safe anaesthesia. After accidental subcutaneous injection, a prolonged and unpredictable duration of neuromuscular block must be presumed, certainly if additional intravenous doses of NMBDs were administered. Quantitative monitoring of the neuromuscular block should always be applied as there is a risk for ongoing neuromuscular block. Ideally the application of the TOF monitoring should take place at the start of induction of anaesthesia to assess the onset of the neuromuscular block. After suspected extravasation of NMBDs, we advise TOF measurement before an additional intravenous dose of NMBD is administered to accommodate anaesthesia best practices. NMBDs might have a delayed absorption from subcutaneous tissue, therefore, spontaneous recovery or stabilisation of the neuromuscular block must be observed before reversal. Prolonged ventilation and sedation may be required at the end of the surgery.
Once the TOF count or ratio is increasing, reversal of NMBDs can be obtained with sugammadex and neostigmine. Though, because of its pharmacological profile and the possibility of a prolonged neuromuscular block, sugammadex is the product of choice after aminosteroid NMBDs.^16,17^ Not only can any further absorbed NMBDs be neutralised by the circulating sugammadex, it also has no unwanted muscarinic side effects, less residual muscle paralysis and a longer elimination half-life compared with neostigmine (100 to 150 vs. 50 to 90 min).^18^ Sugammadex has been associated with perioperative anaphylaxis, though the incidence is rare.^19^ A local subcutaneous injection of sugammadex could theoretically encapsulate aminosteroid NMBDs, yet this remains to be explored.
When a TOF ratio of greater than 0.9 is observed, the patient can be safely extubated.^20^ Monitoring after extubation should include regular measurement of the neuromuscular block, full ASA-monitoring and extended stay in a postanaesthesia care unit (PACU) for a minimum of 4 to 5 h. This prolonged observation is certainly important when long acting NMBDs are used. If there is a decline in TOF ratio during this period of observation, an additional dose of sugammadex is necessary when an aminosteroid NMBD has been used. If the maximum dosage of neostigmine is given to reverse a neuromuscular block caused by a nonaminosteroid NMBD and this results in an insufficient recovery of TOF ratio, we advise not to repeat the dose but to observe the patient in the ICU under prolonged sedation and ventilation.
We would like to highlight that the recommendations in our clinical pathway include guidelines that were not studied or explored but rather based on clinical expertise and scientific basis. Further research is required to assess any clinical benefit.
Extravasation of NMBDs is a potentially dangerous complication that requires adequate anaesthetic management. Current literature consists of articles with heterogeneous data. The available literature suggests that extravasation of NMBDs can result in a neuromuscular block with delayed onset and prolonged and unpredictable duration. Currently, no guidelines exist on how to approach an accidental subcutaneous administration of NMBDs. Therefore, we suggest a clinical pathway that can be used after extravasation of NMBDs. This pathway includes observation with thorough monitoring, the potential need for prolonged sedation and ventilation and a suggested method to reverse the neuromuscular block.
Assistance with the none.
Financial support and none.
Conflicts of none.
Presentation: none.
This manuscript was handled by Dan Longrois.